Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence
Myron S. Cohen
New England Journal of Medicine (2020) Vol. 383, Iss. 6, pp. 585-586
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
David R. Boulware, Matthew F Pullen, Ananta Bangdiwala, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 6, pp. 517-525
Open Access | Times Cited: 1366
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option
Tiantian Yao, Jiandan Qian, Wen‐Yan Zhu, et al.
Journal of Medical Virology (2020) Vol. 92, Iss. 6, pp. 556-563
Open Access | Times Cited: 483
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
Benjamin S. Abella, Eliana L. Jolkovsky, Barbara Biney, et al.
JAMA Internal Medicine (2020) Vol. 181, Iss. 2, pp. 195-195
Open Access | Times Cited: 192
Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19
Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, et al.
JAMA Network Open (2021) Vol. 4, Iss. 4, pp. e216468-e216468
Open Access | Times Cited: 127
State of Sweat: Emerging Wearable Systems for Real-Time, Noninvasive Sweat Sensing and Analytics
Roozbeh Ghaffari, Da Som Yang, Joohee Kim, et al.
ACS Sensors (2021) Vol. 6, Iss. 8, pp. 2787-2801
Open Access | Times Cited: 112
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal
Mohammad Sultan Khuroo
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 3, pp. 106101-106101
Open Access | Times Cited: 117
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
Nicholas J. White, James A Watson, Richard M. Hoglund, et al.
PLoS Medicine (2020) Vol. 17, Iss. 9, pp. e1003252-e1003252
Open Access | Times Cited: 117
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses
Anna Artese, Valentina Svicher, Giosuè Costa, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100721-100721
Open Access | Times Cited: 98
Nanocarrier vaccines for SARS-CoV-2
Jatin Machhi, Farah Shahjin, Srijanee Das, et al.
Advanced Drug Delivery Reviews (2021) Vol. 171, pp. 215-239
Open Access | Times Cited: 90
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
Omkar Indari, Shweta Jakhmola, E. Manivannan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 86
Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review
Sultan AM Saghir, Naif A. Al-Gabri, Mahmoud Alagawany, et al.
Therapeutics and Clinical Risk Management (2021) Vol. Volume 17, pp. 371-387
Open Access | Times Cited: 63
Artificial intelligence, drug repurposing and peer review
Jeremy M. Levin, Tudor I. Oprea, Sagie Davidovich, et al.
Nature Biotechnology (2020) Vol. 38, Iss. 10, pp. 1127-1131
Open Access | Times Cited: 68
Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19
Ali S. Omrani, Sameer A. Pathan, Sarah A. Thomas, et al.
EClinicalMedicine (2020) Vol. 29-30, pp. 100645-100645
Open Access | Times Cited: 66
COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics
Allison P. Spihlman, Nirupa Gadi, Samantha Wu, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 60
Stem cell therapy for COVID‐19: Possibilities and challenges
Mahmood S. Choudhery, David T. Harris
Cell Biology International (2020) Vol. 44, Iss. 11, pp. 2182-2191
Open Access | Times Cited: 57
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline
Serena Bugatti, Ludovico De Stefano, Francesca Bobbio‐Pallavicini, et al.
RMD Open (2020) Vol. 6, Iss. 3, pp. e001323-e001323
Open Access | Times Cited: 54
COVID‐19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations
Bin Zhou, Shinsuke Kojima, Atsuhiko Kawamoto, et al.
Journal of Medical Virology (2020) Vol. 93, Iss. 5, pp. 2694-2704
Open Access | Times Cited: 51
Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19
Fahadul Islam, Shabana Bibi, Atkia Farzana Khan Meem, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12638-12638
Open Access | Times Cited: 50
Nanocomposite based on green synthesis of gold nanoparticles decorated with functionalized multi-walled carbon nanotubes for the electrochemical determination of hydroxychloroquine
N. NARDI, Luan Gabriel Baumgarten, Juliana Priscila Dreyer, et al.
Journal of Pharmaceutical and Biomedical Analysis (2023) Vol. 236, pp. 115681-115681
Closed Access | Times Cited: 18
Potential therapeutic effects and nano-based delivery systems of mesenchymal stem cells and their isolated exosomes to alleviate acute respiratory distress syndrome caused by COVID-19
Mohsen Ghiasi, Peyman Kheirandish Zarandi, Abdolreza Dayani, et al.
Regenerative Therapy (2024) Vol. 27, pp. 319-328
Open Access | Times Cited: 6
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection
Marco Infante, Camillo Ricordi, Rodolfo Alejandro, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 1, pp. 5-16
Open Access | Times Cited: 43
MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2
Lucia Natarelli, Luca Parca, Tommaso Mazza, et al.
Non-Coding RNA (2021) Vol. 7, Iss. 1, pp. 14-14
Open Access | Times Cited: 38
Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19
Dhavan Sharma, Feng Zhao
npj Regenerative Medicine (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 36
Contradictory or complementary? Stakeholders’ perceptions of a circular economy for single-use plastics
Małgorzata Grodzińska‐Jurczak, Aleksandra Krawczyk, Arash Akhshik, et al.
Waste Management (2022) Vol. 142, pp. 1-8
Closed Access | Times Cited: 19
Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2
N. R. Jena
Chemical Physics Impact (2021) Vol. 2, pp. 100011-100011
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top